Welcome to LookChem.com Sign In|Join Free
  • or
2-[3-(pyridin-4-yl)-ureido]-benzoic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

124420-83-3

Post Buying Request

124420-83-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

124420-83-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 124420-83-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,4,4,2 and 0 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 124420-83:
(8*1)+(7*2)+(6*4)+(5*4)+(4*2)+(3*0)+(2*8)+(1*3)=93
93 % 10 = 3
So 124420-83-3 is a valid CAS Registry Number.

124420-83-3Downstream Products

124420-83-3Relevant academic research and scientific papers

DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS

-

Page 37; 39, (2008/06/13)

The present invention relates to novel diarylurea derivatives useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.

N-phenyl-N'-pyridinylureas as anticonvulsant agents

Pavia,Lobbestael,Taylor,Hershenson,Miskell

, p. 854 - 861 (2007/10/02)

A series of N-phenyl-N'-pyridinylureas was examined for anticonvulsant activity. Extensive structure/activity investigations revealed optimal activity in the N-(2,6-disubstituted-phenyl)-N'-(4-pyridinyl)urea series, with 37 exhibiting the best overall anticonvulsant profile. Compound 37 was effective against seizures induced by maximal electroshock but did not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that 37 would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound 37 was selected for Phase 1 clinical trials.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 124420-83-3